Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.73
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million

Reuters
·
Aug 06

Cullinan Q2 FY26 Net Loss Narrows 23.36% to $53.7 Million

Reuters
·
Aug 06

Cullinan Therapeutics Q2 Cash & Investments USD 356 Million

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 EPS USD -0.81 VS. Ibes Estimate USD -0.81

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 Operating Expenses USD 57.254 Million

THOMSON REUTERS
·
Aug 06

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06

Will FDA-Backed Registrational Phase 2 for CLN-049 Redefine Cullinan Therapeutics' (CGEM) Narrative?

Simply Wall St.
·
Aug 03

Cullinan Therapeutics price target raised to $39 from $38 at BTIG

TIPRANKS
·
Jul 29

Cullinan Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 29

Analysts’ Top Healthcare Picks: Kiniksa Pharmaceuticals (KNSA), Cullinan Management (CGEM)

TIPRANKS
·
Jul 28

Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA

TIPRANKS
·
Jul 28

Cullinan to Launch Registrational Phase 2 Cln-049 Trial in Relapsed/refractory AML in Q3 2026

Reuters
·
Jul 28

Cullinan Therapeutics - to Initiate Phase 2 Registrational Study of Cln-049 in Aml in Q3 2026

THOMSON REUTERS
·
Jul 28

Cullinan Therapeutics - Phase 2 Study to Include Dose-Optimization and Single-Arm Cohort at Recommended Dose

THOMSON REUTERS
·
Jul 28

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for Cln-049 and Advances Program to a Potentially Registrational Phase 2 Study in Aml

THOMSON REUTERS
·
Jul 28

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

GlobeNewswire
·
Jul 28

Cullinan Therapeutics management to meet with BTIG

TIPRANKS
·
Jul 15

Cullinan Therapeutics CSO Jennifer Michaelson Sells 8,000 Common Shares for $142,560

Reuters
·
Jul 08

H.C. Wainwright Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
Jun 24

Cullinan Therapeutics shareholders elect two Class III directors at annual meeting

Reuters
·
Jun 17